4.3 Article

Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Rheumatology

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

Sofia Ramiro et al.

Summary: The ASAS-EULAR recommendations provide updated guidance on the management of axial spondyloarthritis, including treatment targets, non-pharmacological interventions, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) as the first-line pharmacological treatment. For patients with comorbidities, the use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) is recommended. The recommendations also cover the management of extramusculoskeletal manifestations, tapering of bDMARDs, and surgical interventions.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial

Jessica A. Walsh et al.

Summary: This study evaluated the effect of ixekizumab on self-reported functioning and health in patients with active nonradiographic axial spondyloarthritis. The results showed that ixekizumab treatment resulted in significant improvement in physical functioning, role-physical, and bodily pain at weeks 16 and 52. Patients receiving ixekizumab every 2 weeks reported greater improvements in ASAS health index and EQ-5D-5L compared to placebo. Overall, ixekizumab therapy was superior to placebo in improving self-reported functioning and health in patients with nonradiographic axial spondyloarthritis.

ARTHRITIS CARE & RESEARCH (2022)

Article Rheumatology

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial

Desiree van der Heijde et al.

Summary: This study evaluated the efficacy and safety of upadacitinib in patients with active ankylosing spondylitis who had an inadequate response to biological disease-modifying antirheumatic drugs. The results showed that upadacitinib was significantly more effective than placebo over a 14-week treatment period, and no new safety risks were identified.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Article Rheumatology

Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial

Atul Deodhar et al.

Summary: The study demonstrates that treatment with Ixekizumab in non-radiographic axial spondyloarthritis patients can lead to significant improvements as early as week 1, with ASAS40 responders showing greater improvements in all response domains and fatigue and spinal pain at night compared to ASAS20 non-responders.

RHEUMATOLOGY AND THERAPY (2021)

Review Rheumatology

Patient Burden of Axial Spondyloarthritis

Vibeke Strand et al.

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2017)

Review Medicine, General & Internal

Axial spondyloarthritis

Joachim Sieper et al.

LANCET (2017)

Review Rheumatology

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis

Desiree van der Heijde et al.

ANNALS OF THE RHEUMATIC DISEASES (2017)

Article Rheumatology

Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis

LC Doward et al.

ANNALS OF THE RHEUMATIC DISEASES (2003)